Marker Therapeuticsincis A Clinical Stage Immuno Oncology Company Based In Houstontexasthe Company Focuses On Developing And Commercializing Innovative T Cell Based Immunotherapies To Address Unmet Needs In Oncologyparticularly For Blood Cancers And Solid Tumorsmarker Therapeutics Is Committed To Discovering And Delivering Novel T Cell Therapies That Target Multiple Tumor Antigensits Proprietary Multi Antigen Targetedmultitaatechnology Allows For The Selective Expansion Of Tumor Specific T Cells From A Patient S Blood Without Genetic Modificationthe Company S Product Pipeline Includes Mt 401 For Post Transplant Acute Myeloid Leukemia And Mt 601 For Advanced Unresectable Pancreatic Cancermarker Therapeutics Also Conducts Clinical Studies For Various Cancer Typesincluding Acute Myeloid Leukemianon Hodgkinae S Lymphomamultiple Myelomaand Breast Cancerthe Company S Strategic Advantage Lies In Its Unique Technology Platformwhich Aims To Improve Safety And Efficacy In Cancer Treatment While Reducing Manufacturing Complexitymarker Therapeutics Holds Intellectual Property That Protects Its Platform And Product Candidatesreinforcing Its Position In The Market
No conferences found for this company.
| Company Name | Marker Therapeutics Inc |
| Country |
United States
|
| Address | N/A |
| Telephone | N/A |
| N/A |
